These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Finn OJ Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931 [TBL] [Abstract][Full Text] [Related]
9. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Becht E; Giraldo NA; Germain C; de Reyniès A; Laurent-Puig P; Zucman-Rossi J; Dieu-Nosjean MC; Sautès-Fridman C; Fridman WH Adv Immunol; 2016; 130():95-190. PubMed ID: 26923001 [TBL] [Abstract][Full Text] [Related]
10. Targeting the tumor microenvironment to enhance antitumor immune responses. Van der Jeught K; Bialkowski L; Daszkiewicz L; Broos K; Goyvaerts C; Renmans D; Van Lint S; Heirman C; Thielemans K; Breckpot K Oncotarget; 2015 Jan; 6(3):1359-81. PubMed ID: 25682197 [TBL] [Abstract][Full Text] [Related]
11. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. Albini A; Bruno A; Noonan DM; Mortara L Front Immunol; 2018; 9():527. PubMed ID: 29675018 [TBL] [Abstract][Full Text] [Related]
12. [Intratumoral B cells and tertiary lymphoid structures are biomarkers of survival and immunotherapy responses]. Fridman WH; Petitprez F; Sautes-Fridman C Bull Cancer; 2020 Apr; 107(4):403-404. PubMed ID: 32284150 [No Abstract] [Full Text] [Related]
13. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC. Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348 [TBL] [Abstract][Full Text] [Related]
14. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies. Trüb M; Zippelius A Front Immunol; 2021; 12():674565. PubMed ID: 34054861 [TBL] [Abstract][Full Text] [Related]
15. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Johansson-Percival A; He B; Li ZJ; Kjellén A; Russell K; Li J; Larma I; Ganss R Nat Immunol; 2017 Nov; 18(11):1207-1217. PubMed ID: 28892469 [TBL] [Abstract][Full Text] [Related]
16. Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy. Bule P; Aguiar SI; Aires-Da-Silva F; Dias JNR Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575965 [TBL] [Abstract][Full Text] [Related]